Argentina

9 Vaccines Approved for Use in Argentina

RNA

Moderna

Spikevax

Approved in 86 countries
63 trials in 22 countries
Approval Source: saludneuquen.gob.ar
RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
80 trials in 26 countries
Approval Source: riotimesonline.com
Non Replicating Viral Vector

CanSino

Convidecia

Approved in 10 countries
13 trials in 6 countries
Approval Source: apnews.com
Non Replicating Viral Vector

Gamaleya

Sputnik Light

Approved in 26 countries
7 trials in 3 countries
Approval Source: tass.com
Non Replicating Viral Vector

Gamaleya

Sputnik V

Approved in 74 countries
24 trials in 7 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
63 trials in 30 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Serum Institute of India

Covishield (Oxford/ AstraZeneca formulation)

Approved in 49 countries
4 trials in 1 country
Approval Source: batimes.com.ar
Inactivated

Sinopharm (Beijing)

Covilo

Approved in 91 countries
29 trials in 12 countries
Approval Source: xinhuanet.com
Inactivated

Sinovac

CoronaVac

Approved in 56 countries
37 trials in 9 countries
Approval Source: xinhuanet.com

10 in Clinical Trials in Argentina

VLP

Medicago

Covifenz

Approved in 1 country
6 trials in 6 countries
RNA

Moderna

Spikevax

Approved in 86 countries
63 trials in 22 countries
RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
80 trials in 26 countries
Non Replicating Viral Vector

CanSino

Convidecia

Approved in 10 countries
13 trials in 6 countries
Non Replicating Viral Vector

Gamaleya

Sputnik Light

Approved in 26 countries
7 trials in 3 countries
Non Replicating Viral Vector

Gamaleya

Sputnik V

Approved in 74 countries
24 trials in 7 countries
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
63 trials in 30 countries
Non Replicating Viral Vector

ReiThera

GRAd-COV2

5 trials in 12 countries
Inactivated

Sinopharm (Beijing)

Covilo

Approved in 91 countries
29 trials in 12 countries

1 Vaccines with Trials in Argentina are No Longer Progressing

RNA

Curevac

CVnCoV

9 trials in 12 countries